Navigation Links
ABR -- Affinity BioReagents Announces Launch of New Website
Date:10/12/2007

ture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand(R).

With more than 35,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry -- research antibodies that are 100% quality guaranteed or your money back -- with no questions asked.

Utilizing a distribution network encompassing over 55 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR -- Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.


'/>"/>
SOURCE ABR -- Affinity BioReagents
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Extensive Campaigning To Warn Against Children’s Growing Affinity To Fast Food In Britai
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...fering from the most common form of brain cancer m...y and // chemotherapy than radiotherapy alone . Ba... people with the type of cancer known as glioblast... the cancer as safely possible and then undergo ra...
...g the opinion that dairy products provide the nece...In a study conducted recently on collected informa...children and adolescence and consumption of dairy ...ip between the two. Children are often advised to ...
...nted at American College of Cardiology, laughter c...ief presenter of the paper Michael Miller, MD, dir...associate professor of medicine at the University ...sion after studying 300 participants, 150 healthy ...
...y thought of as a characteristic trait of man. Oft...ly acceptable attributes of man. But can it be lin...ecent study in the current issue of Biological Psy... ratio is the ratio of second finger or index fing...
Other Medicine News:
(Date:8/28/2008)... VIENNA, Austria, Aug. 28 /- Inte...aborator Merck & Co., Inc. has initiated a Phase I...ne for the prevention of,Staphylococcus aureus (S....,placebo controlled study aims to evaluate the saf... patients with end-stage kidney disease on,hemodia...
(Date:8/27/2008)... - Patients in the VELCADE, melphalan and predn...nefit as well as a 30 percent complete response -,...nium: The Takeda,Oncology Company today announced ...andomized, Phase III VISTA(1) trial in this week,s...he results showed a significant survival,benefit a...
(Date:8/27/2008)... - First Phase 3 data, from BLISS-52 trial, e...trial, BLISS-76, expected by fall 2009 -, ROCKVIL...enome,Sciences, Inc. (Nasdaq: HGSI ) today announ... in BLISS-76, the second of two pivotal Phase 3,ra...umab) in patients with,active systemic lupus eryth...
(Date:8/26/2008)... INDIANAPOLIS, Aug. 26 /- Semafor...th International Congress on Targeted Therapies,in...ery of novel,multi-targeted kinase inhibitors that...eclinical studies., A novel and proprietary molec...al modeling allowing for the design of pan-PI3 kin...
Breaking Medicine Technology:Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 2Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3Medicare Prescription Drug Benefit Nonprofit Hospitals Ambulatory Surgery Centers Statistical Methods and Pay For Performance Highlighted In the L 1162 1Medicare Prescription Drug Benefit Nonprofit Hospitals Ambulatory Surgery Centers Statistical Methods and Pay For Performance Highlighted In the L 1162 2Medicare Prescription Drug Benefit Nonprofit Hospitals Ambulatory Surgery Centers Statistical Methods and Pay For Performance Highlighted In the L 1162 3Spectranetics to Appeal Decision in Patent Litigation 1160 1Spectranetics to Appeal Decision in Patent Litigation 1160 2Spectranetics to Appeal Decision in Patent Litigation 1160 3Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 552 1Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 552 2ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference 550 1ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference 550 2
... Calif.--(BUSINESS WIRE)--Jun 11, 2007 - Geron,Cor...ation of,research studies indicating that GRNOPC1,...sed therapeutic for the treatment of,spinal cord i...system., Presented by Geron scientist Ross Okamura...s meeting in San Diego, the findings,could mean th...
..., June 11, 2007-ReGen is pleased to announce that,... Colostrinin, its,nutraceutical product which the ...thy cognitive function, was presented today at the...n Surfers,Paradise, Queensland, Australia by Dr Ma...he conference, which is being attended by key opin...
Other Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Data Showing that ReGen's Colostrinin Supports Healthy Cognitive,Function Presented at the 2007 International Congress on Natural,Medicine in Australia 2
Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discou
...clusive Measuring System delivers precise and accu...eel they are receiving a better examination when t...ipment. ,User Friendly - after only 5 minutes of...ome very proficient in the operation of this instr...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve
Sleeve extends 3mm beyond end, .90mm (20G) probe, 1.4mm (17G) sleeve
Medicine Products: